IFN-γ receptor deficiency prevents diabetes induction by diabetogenic CD4 + T cells but not CD8 + T cells by Yi, Zuoan et al.
IFN-γ receptor deficiency prevents diabetes induction by
diabetogenic CD4+ T cells but not CD8+ T cells1
Zuoan Yi*, Li Li*, Alaina Garland*, Qiuming He*, Haidong Wang†, Jonathan D Katz‡, Roland
Tisch*, and Bo Wang*
*Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, USA
†Department of Endocrinology, Huadong Hospital, Fudan University, Shanghai, China
‡Diabetes Research Center, Cincinnati Children’s Research Foundation, and Division of
Endocrinology, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati,
USA
Summary
IFN-γ is generally believed to be important in the autoimmune pathogenesis of type 1 diabetes
(T1D). However, the development of spontaneous β cell autoimmunity is unaffected in NOD mice
lacking expression of IFN-γ or the IFN-γ receptor (IFNγR), bringing into question the role IFN-γ
has in T1D. In the current study an adoptive transfer model was employed to define the
contribution of IFN-γ in CD4+ versus CD8+ T cell-mediated β cell autoimmunity. NOD.scid mice
lacking expression of the IFNγR β chain (NOD.scid.IFNγRBnull) developed diabetes following
transfer of β cell-specific CD8+ T cells alone. In contrast, β cell-specific CD4+ T cells alone failed
to induce diabetes despite significant infiltration of the islets in NOD.scid.IFNγRBnull recipients.
The lack of pathogenicity of CD4+ T cell effectors was due to the resistance of IFNγR-deficient β
cells to inflammatory cytokine-induced cell death. On the other hand, CD4+ T cells indirectly
promoted β cell destruction by providing help to CD8+ T cells in NOD.scid.IFNγRBnull recipients.
These results demonstrate that IFN-γR may play a key role in CD4+ T cell-mediated β cell
destruction.
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Introduction
The development of spontaneous type 1 diabetes (T1D) is the result of autoimmune
destruction of the insulin-producing β cells. The primary immune effectors of β cell
destruction are CD8+ and CD4+ T cells that exhibit a type 1 phenotype [1]. CD8+ T effector
cells kill β cells directly through granzyme B-mediated cytotoxicity upon recognition of
MHC-peptide complexes presented on the surface of β cells. Both CD4+ and CD8+ T
effector cells also mediate β cell destruction indirectly through secretion of proinflammatory
cytokines. IFN-γ has long been believed to play a key role in driving the autoimmune
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pathogenesis of T1D [2, 3]. How IFN-γ contributes to β cell autoimmunity and T1D
development remains unclear, however.
Studies have shown that blocking IFN-γ function in NOD mice with either IFN-γ-specific
Abs [4, 5] or soluble IFN-γ receptors (IFNγR) [6] reduces the incidence of spontaneous
diabetes and prevents diabetes transfer by splenocytes from diabetic NOD donor mice [7].
Furthermore, transgenic expression of IFN-γ by β cells induces autoimmunity resulting in
overt diabetes in otherwise diabetes-resistant mice [8]. In vitro studies have also shown that
IFN-γ has cytotoxic effects on β cells. Exposure of human and murine islets to IFN-γ with
either IL-1β or TNF-α induces β-cell death in vitro [9-14]. IFN-γ alone, however, has no
effect on β cell-death. Notably, β cells deficient of STAT-1, a key signaling molecule
activated in β cells by IFN-γ, are resistant to apoptosis induced in vitro by IFN-γ with either
IL-1β or TNF-α [12, 15, 16].
Nevertheless, despite IFN-γ being the signature cytokine of type 1 effector T cells, the
differentiation of type 1 effector T cells and the development of spontaneous diabetes are
not significantly affected in NOD mice genetically lacking expression of IFN-γ [17] or
IFNγR [18, 19]. T cells from IFNγR β chain (IFNγRB)-deficient NOD mice
(NOD.IFNγRBnull) transfer diabetes as efficiently as wild-type NOD T cells [20]. Although
NOD mice lacking IFNγR α chain expression were reported to remain diabetes-free, it was
later found that disease protection was independent of the IFNγR deficiency, and due to
linked genes derived from the 129 mouse strain genotype [18, 21]. Furthermore, NOD mice
in which the IFN-γ-mediated signaling in β cells is selectively disrupted by expression of
dominant negative mutants of IFNγR develop spontaneous diabetes comparable to wild-type
NOD mice [22]. The fact that the lack of IFNγR expression has little or no effect on the
development of spontaneous diabetes in NOD mice is perplexing in view of studies showing
an important role for IFN-γ in autoimmune destruction of β cells in vitro and in vivo [2, 3].
In the current study, we employed an adoptive transfer model to determine how IFNγR
deficiency influences the development of diabetes mediated by diabetogenic CD4+ versus
CD8+ T cells. Our results demonstrate that IFNγR deficiency has a distinct effect on the
development of diabetes mediated by CD4+ T cells versus CD8+ T cells, which was
previously unrecognized in IFNγR-deficient NOD mice. These findings provide new insight
into the mechanisms by which IFN-γ contributes to the pathogenesis of T1D.
Results
Diabetogenic CD8+ T cells induce diabetes in IFNγR-deficient NOD.scid mice
Previous studies have demonstrated that systemic deficiency of either the α or β chain of
IFNγR has a minimal effect on the development of spontaneous diabetes in NOD mice [18,
19]. These model systems are limited, however, since the possibility that IFNγR deficiency
has differential effects on CD4+ and CD8+ T cell-mediated β-cell autoimmunity cannot be
addressed. Accordingly, an adoptive transfer model was employed to individually assess the
impact of IFNγR deficiency on the pathogenicity of diabetogenic CD4+ versus CD8+ T
effectors. NOD.scid mice lacking expression of the IFNγR β chain (NOD.scid.IFNγRBnull)
were used as recipients in this study. Initially, splenocytes from wild-type NOD mice were
adoptively transferred into NOD.scid and NOD.scid.IFNγRBnull mice, and diabetes
monitored. All of the NOD.scid.IFNγRBnull and NOD.scid recipients developed diabetes
although diabetes onset was delayed in NOD.scid.IFNγRBnull mice (Fig. 1A). These results
are consistent with previous observations that NOD mice lacking IFNγR expression
continue to develop spontaneous diabetes [18, 19].
Yi et al. Page 2













To determine whether IFNγR deficiency selectively affected CD8+ T cell-mediated β cell
destruction, TCR transgenic CL4 CD8+ T cells specific for influenza hemagglutinin (HA)
were adoptively transferred into NOD.scid.InsHA or NOD.scid.InsHA.IFNγRBnull mice. All
recipients of CL4 CD8+ T cells developed diabetes regardless of genotype (Fig. 1B),
although the onset of diabetes was delayed in some of the NOD.scid.InsHA.IFNγRBnull
recipients. These results demonstrate that CD8+ T cells continue to mediate β cell
destruction despite the lack of IFNγR expression in recipient animals.
Diabetogenic CD4+ T cells induce insulitis but fail to transfer diabetes in IFNγR-deficient
NOD.scid recipients
Next, the effect of IFNγR deficiency on CD4+ T cell-mediated diabetes was investigated.
BDC2.5 CD4+ T cells were isolated from the spleen of BDC2.5.NOD.Cαnull mice, which
lack CD8+ T cells, and then injected into NOD.scid.IFNγRBnull and NOD.scid mice. As
expected, diabetes was induced in all NOD.scid recipients 9 wks post-transfer. Strikingly,
none of the NOD.scid.IFNγRBnull recipients of BDC2.5 CD4+ T cells developed diabetes
over 20 wks post-transfer (Fig. 1C). Histological analysis of the pancreases showed that
NOD.scid mice receiving BDC2.5 CD4+ T cells developed severe insulitis by 5 wks post-
transfer (Fig. 2). In contrast, insulitis was significantly reduced in NOD.scid.IFNγRBnull
recipients with the majority of the islets remaining free of infiltration. By 15 wks post-
transfer, however, NOD.scid.IFNγRBnull recipients exhibited significant insulitis (Fig. 2).
The delayed onset and progression of insulitis in NOD.scid.IFNγRBnull recipients could be
attributed to inefficient priming of the transferred BDC2.5 CD4+ T cells. To test this
possibility, CFSE-labeled BDC2.5 CD4+ T cells were transferred into NOD.scid and
NOD.scid.IFNγRBnull mice, and T cell activation and proliferation assessed in the spleen,
mesenteric lymph nodes (MLN), draining pancreatic lymph nodes (PLN) and islets. As
reported previously [23], early proliferation of BDC2.5 CD4+ T cells was detected in the
PLN but not the spleen and MLN of NOD.scid.IFNγRBnull and NOD.scid recipients 3 to 4
days post-transfer (data not shown), and few cells were found in the islets at this time. At
day 6 post-transfer, over 50% of BDC2.5 CD4+ T cells in the PLN of both
NOD.scid.IFNγRBnull and NOD.scid recipients had proliferated and undergone more than
seven rounds of division as measured by CFSE dilution (Fig. 3A). The proliferation of
BDC2.5 CD4+ T cells in the PLN was antigen-specific because there were few proliferating
BDC2.5 CD4+ T cells (less than 10%) in the spleen and MLN of both groups of recipients
(data not shown). Proliferating T cells in both groups of animals exhibited up-regulation of
CD44 and down-regulation of CD62L (Fig. 3A). Thus, the lack of IFNγR expression by
recipient animals had no effect on priming of the transferred BDC2.5 CD4+ T cells in the
draining PLN.
On the other hand BDC2.5 CD4+ T cells displayed a markedly different profile in the islets
of NOD.scid.IFNγRBnull versus NOD.scid recipients. Significant numbers of activated and
proliferating BDC2.5 CD4+ T cells were detected in the islets of NOD.scid recipients (Fig.
3B). In contrast, only few BDC2.5 CD4+ T cells were found in the islets of
NOD.scid.IFNγRBnull recipients, which in turn exhibited minimal proliferation and
activation (Fig. 3B). These results indicate that trafficking of the transferred BDC2.5 CD4+
T cells to the islets is delayed in NOD.scid.IFNγRBnull recipients, thereby explaining the
later onset and progression of insulitis in these animals (Fig. 2).
Albeit delayed, NOD.scid.IFNγRBnull recipients of BDC2.5 CD4+ T cells developed severe
insulitis (Fig. 2) suggesting that IFNγR-deficient β cells were resistant to ongoing
inflammation. To better assess the functional status of the β cell mass in these recipients, an
intraperitoneal glucose tolerance test (IPGTT) was performed [24]. Twenty weeks post-
transfer of BDC2.5 CD4+ T cells, NOD.scid.IFNγRBnull recipients were injected i.p. with
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glucose and blood glucose levels measured. As expected, recently diabetic NOD mice in
which the majority of β cells have been destroyed, failed to control hyperglycemia after
glucose injection (Fig. 4A). Pre-diabetic BDC2.5.NOD.Cαnull mice that are known to
develop destructive insulitis exhibited elevated blood glucose levels that persisted after
glucose administration, reflecting impaired β cell function. Despite severe insulitis, blood
glucose was similarly controlled in NOD.scid.IFNγRBnull recipients of BDC2.5 CD4+ T
cells and untreated NOD.scid mice that have normal β cell mass and function (Fig. 4A).
Together these results demonstrate that IFNγR-deficient β cells are resistant to CD4+ T cell-
mediated destruction.
Lack of pathogenicity of CD4+ T cells in IFNγR-deficient mice is due to the resistance of β
cells to IFN-γ-induced death
To further assess the extent to which IFNγR-deficient β cells were resistant to CD4+ T cell-
mediated killing, NOD.scid.IFNγRBnull mice were treated with cyclophosphamide (CY)
after the transfer of BDC2.5 CD4+ T cells. Treatment with CY accelerates diabetes
development in NOD mice [4, 5] by in part enhancing inflammatory cytokine and
chemokine production by islet infiltrating cells [25]. NOD.scid.IFNγRBnull recipients were
injected with CY 20 wks after BDC2.5 CD4+ T cell transfer, and monitored for diabetes. As
controls, NOD.scid recipients of BDC2.5 CD4+ T cells prior to diabetes onset and pre-
diabetic BDC2.5.NOD.Cαnull mice with established insulitis were also treated with CY. All
NOD.scid recipients of BDC2.5 CD4+ T cells and pre-diabetic BDC2.5.NOD.Cαnull mice
developed diabetes within 2 wks after one injection of CY (Fig. 4B). In contrast, the
majority of CY treated NOD.scid.IFNγRBnull recipients (12/14) remained diabetes-free,
even after a second injection of CY (Fig. 4B). This result demonstrates that IFNγR-deficient
β cells are highly resistant to BDC2.5 CD4+ T cell-mediated destruction, even when the
proinflammatory milieu of the islets is enhanced.
To determine whether the failure of BDC2.5 CD4+ T cells to transfer diabetes in
NOD.scid.IFNγRBnull mice was β cell-intrinsic, two sets of experiments were carried out. In
the first, bone-marrow chimera were established in which β cells lacked IFNγR expression.
NOD.scid.IFNγRBnull and NOD.scid mice were irradiated and reconstituted with bone
marrow from NOD.scid mice to restore IFNγR expression by all hematopoietically-derived
APC [26]. Eight wks after bone marrow reconstitution, animals were adoptively transferred
with BDC2.5 CD4+ T cells and monitored for diabetes. All control chimeric NOD.scid
recipients of BDC2.5 CD4+ T cells (10/10) became diabetic by 78 days post-transfer (Fig.
5), whereas the majority (6/8) of chimeric NOD.scid.IFNγRBnull mice receiving BDC2.5
CD4+ T cells remained diabetes-free when monitored for over 20 wks (Fig. 5).
Secondly, IFNγR-deficient β cells were tested in vitro for sensitivity to cytokine-induced
death. Wild-type and IFNγR-deficient β cells were incubated with IFN-γ plus IL-1β or TNF-
α, and β cell death measured. As shown in Fig. 6, significant death of wild-type β cells was
readily induced by exposure to IFN-γ plus either IL-1β or TNF-α. In contrast, the same
treatment had a minimal effect on the viability of IFNγR-deficient β cells, similar to β cells
exposed to individual cytokines. Studies have also shown that the combination of TNF-α
and IL-1β is cytotoxic to β cells [27]. Interestingly, the death of IFNγR-deficient β cells
treated with TNF-α and IL-1β was significantly reduced compared to wild-type β cells (Fig.
6). Together these results suggest that the lack of diabetes in NOD.scid.IFNγRBnull mice
following BDC2.5 CD4+ T cell transfer is due to resistance of β cells to proinflammatory
cytokine-induced cell death.
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CD4+ T cells accelerate the onset of diabetes induced by CD8+ T cells in
NOD.scid.IFNγRBnull mice
Despite the inability of CD4+ T cells to kill β cells lacking IFNγRB expression (Fig. 1C),
NOD.IFNγRnull mice have been shown to develop spontaneous diabetes. This suggests a
scenario in which CD4+ T cells in NOD.IFNγRnull mice provide help to CD8+ T cells that
directly destroy β cells. To test this hypothesis, 8.3 CD8+ T cells which express a transgenic
TCR specific for glucose-6-phosphatase catalytic subunit-related protein (IGRP) were
transferred alone or with CD4+ T cells from NOD mice into NOD.scid.IFNγRBnull or
control NOD.scid mice. 8.3 CD8+ T cells were used based on previous work showing that
CD4+ T cells are required for IGRP-specific 8.3 CD8+ T cells to efficiently mediate diabetes
[28]. As expected, diabetes onset was accelerated in NOD.scid recipients injected with both
8.3 CD8+ T cells and NOD CD4+ T cells relative to diabetes onset in NOD.scid recipients of
only 8.3 CD8+ T cells (Fig. 7). Diabetes onset in NOD.scid.IFNγRBnull recipients of 8.3
CD8+ T cells alone was delayed compared to that in NOD.scid recipients. In contrast, co-
transfer of NOD CD4+ T cells and 8.3 CD8+ T cells significantly accelerated the onset of
diabetes in the NOD.scid.IFNγRBnull recipients (Fig. 7). These results indicate that CD4+ T
cells nevertheless, contribute to β cell destruction in NOD.scid.IFNγRBnull recipients by
providing help to 8.3 CD8+ T cells.
Discussion
Despite much effort the role(s) of IFN-γ in T1D remains ill-defined. In this study we
employed an adoptive transfer model to dissect the relative contribution of IFN-γ in CD4+
versus CD8+ T cell-mediated β-cell autoimmunity, and in turn better define the function of
this proinflammatory cytokine in the development of T1D. We found that IFNγR deficiency
prevents diabetes induction by β cell-specific CD4+ but not CD8+ T cells. Furthermore, the
resistance of IFNγR-deficient animals to CD4+ T cell-mediated diabetes was primarily due
to the lack of IFNγR expression by β cells.
Consistent with the previous finding reported by Chervonsky and colleagues [20], diabetes
was induced in IFNγR-deficient animals by diabetogenic CD8+ T cells (Figs. 1 & 7). The
minimal impact IFNγR deficiency had on the development of diabetes was not surprising
since CD8+ T cells are known to primarily destroy β cells by a perforin/granzyme B
mechanism. In contrast, β cell-specific BDC2.5 CD4+ T cells failed to transfer diabetes in
NOD.scid.IFNγRBnull recipients (Fig. 1). Our findings differ from results obtained in an
earlier study in which the development of overt diabetes was unaffected in IFNγR-deficient
NOD mice expressing the IAg7-restricted 4.1 transgenic TCR specific for β cells [29]. The
different results seen between the two studies could be due to the animal models used.
NOD4.1 mice possess significant numbers of CD8+ T cells that express the transgenic TCR
β chain paired with endogenous TCR α chains [30]. Some of these CD8+ T cells in IFNγR-
deficient NOD4.1 mice are expected to be β cell-specific, and in turn drive β cell destruction.
Since NOD.BDC2.5.Cαnull mice were used as donors in our study, the transferred BDC2.5
CD4+ T cells were monoclonal, and devoid of CD8+ T cells.
The lack of diabetogenicity by transferred BDC2.5 CD4+ T cells in NOD.scid.IFNγRBnull
recipients was not due to aberrant priming. BDC2.5 CD4+ T cells proliferated similarly in
the PLN of NOD.scid and NOD.scid.IFNγRBnull mice (Fig. 3). Interestingly, the
progression of insulitis by transferred BDC2.5 CD4+ T cells was delayed in
NOD.scid.IFNγRBnull recipients. Impaired homing of insulin B chain specific CD8+ T cells
to the islets of IFNγR-deficient recipients has also been reported [20]. The delayed onset and
progression of islet infiltration by primed BDC2.5 CD4+ T cells is likely due to altered
expression of adhesion molecules in NOD.scid.IFNγRBnull recipients. For instance, IFN-γ is
known to control T cell trafficking by regulating several adhesion molecules expressed by
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endothelial cells [31]. Nevertheless, it is very unlikely that the observed delay in insulitis
accounts for the complete lack of β cell destruction by BDC2.5 CD4+ T cells. Indeed, CY
treatment of NOD.scid.IFNγRBnull mice at a time when the islets were significantly
infiltrated had no effect on diabetes incidence (Fig. 4). This was in marked contrast to
NOD.scid recipients injected with CY, in which the pathogenicity of transferred BDC2.5
CD4+ T cells was enhanced. CY has recently been shown to induce proinflammatory
cytokine secretion by islet infiltrating cells and drive β cell autoimmunity [25]; our results
suggest that IFN-γ is a key effector cytokine in this model.
Evidence is provided demonstrating that the resistance of IFNγR-deficient animals to
BDC2.5 CD4+ T cell-induced diabetes is β cell-intrinsic. β cells lacking IFNγR expression
were no longer sensitive to cytokine-induced cell death in vivo and in vitro. For instance,
BDC2.5 CD4+ T cells failed to transfer diabetes in NOD.scid.IFNγRBnull mice reconstituted
with “wild-type” NOD.scid bone marrow in which hematopoietic-derived cells expressed
IFNγR but not β cells (Fig. 5). Although non-hematopoietic cells, such as endothelial cells,
also lacked IFNγR expression in NOD.scid.IFNγRBnull bone marrow recipients, our in vitro
experiments argue against a role for these cells affecting the diabetogenicity of transferred
BDC2.5 CD4+ T cells. Pakala and colleagues provided data indicating that IFN-γ has no role
in CD4+ T cell-mediated destruction of β cells. In this study IFNγR-deficient islet allografts
were implanted into NOD.scid mice receiving BDC2.5 CD4+ T cells [32]. The observed
destruction of the IFNγR-deficient islets may reflect allograft-rejection mediated by natural
killer (NK) cells. Numerous studies have shown the importance of NK cells in acute
allograft rejection [33, 34]. Our results clearly demonstrate that in vitro cytokine-mediated β
cell death required IFNγR expression by β cells (Fig. 6), consistent with other studies [11,
29]. β cell death has been shown to be readily induced through the synergistic effects of
IFN-γ with IL-1β or TNF-α [12, 15, 35]. It has also been reported that β cells are susceptible
to apoptosis mediated by the combination of TNF-α and IL-1β, presumably independent of
IFN-γ [27]. Therefore it was somewhat surprising that IFNγR-deficient β cells exhibited
reduced sensitivity to the cytotoxic effects of TNF-α and IL-1β (Fig. 6), indicating a central
role for IFN-γ in cytokine-induced β cell death. How IFN-γ-mediated signaling in β cells
governs the susceptibility to TNF-α and IL-1β-mediated death is currently unclear.
However, IFN-γ sensitizes β cells to apoptosis by triggering activation of STAT-1, and
inducing expression of several genes directly or indirectly associated with β cell death,
including IFN-γ regulatory factor-1, caspase-1 and -11 [12, 25]. Furthermore, β cells
pretreated in vitro with IFN-γ are more susceptible to apoptosis when subsequently exposed
to TNF-α and IL-1β [12, 36]. This scenario may explain the resistance of IFNγR-deficient β
cells to TNF-α and IL-1β-induced cell death in vitro and CD4+ T cell-mediated destruction
in vivo.
NOD mice deficient of CD4+ T cells fail to develop insulitis and diabetes [37-39]. Why then
do NOD mice lacking IFNγR or selectively expressing a dominant negative IFNγR by β
cells continue to develop diabetes [18, 19, 22], if our results indicate that CD4+ T cell-
mediated β-cell destruction should be blocked? Co-transfer experiments carried out in this
study demonstrate that IFNγR-deficiency does not impair the helper function of CD4+ T
cells. For example, the onset of CD8+ T cell-induced diabetes was accelerated in
NOD.scid.IFNγRBnull recipients when CD4+ T cells were co-transferred (Fig. 7). These
results suggest that CD4+ T cells indirectly contribute to the development of spontaneous
diabetes in IFNγR-deficient NOD mice by providing help necessary for β cell-specific CD8+
T cells to initiate β-cell autoimmunity and destroy β cells via cytotoxic activity.
Taken together, our study demonstrates that IFNγR-deficiency has distinct effects on CD4+
versus CD8+ T cell-mediated diabetes, and that IFN-γ may play a critical role in CD4+ T
cell-mediated destruction of β cells. These results may also provide an explanation for the
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“unexpected” development of spontaneous diabetes in NOD.IFNγRnull mice [18, 19] and in
NOD mice selectively expressing a dominate negative IFN-γ receptor by β cells [22].
Materials and Methods
Mice
NOD/Lt and NOD.scid mice were bred and maintained under specific pathogen-free
conditions. NOD.IFNγRBnull mice deficient in IFNγR β chain expression have been
characterized [19] and were kindly provided by Dr. D. Serreze (The Jackson Laboratories
Bar Harbor, ME). NOD.IFNγRBnull mice were bred with NOD.scid mice to generate
NOD.scid.IFNγRBnull mice. NOD.BDC2.5 mice expressing an IAg7-restricted transgenic
TCR have been described [40] and were crossed to NOD.Cαnull mice to generate
NOD.BDC2.5.Cαnull mice. NOD.CL4 mice expressing an H2Kd-restricted clone-4 TCR
[41] were bred with NOD.scid mice to generate NOD.scid.CL4 mice.
NOD.scid.InsHA.IFNγRBnull mice were established by breeding NOD.scid.IFNγRBnull
mice with NOD.scid.InsHA mice [42]. NOD.8.3 mice that express an H2Kd-restricted TCR
specific for IGRP [43] have been previously described [28]. All animal experiments were
approved by the University of North Carolina at Chapel Hill Institutional Animal Care and
Use Committees.
Adoptive transfer of diabetes
CL4 CD8+ T cells were purified from the spleen of nondiabetic NOD.scid.CL4 mice by
negative selection according to the manufacturer’s instructions (Miltenyi Biotec), and
adoptively transferred into 6 to 8 wk-old NOD.scid.InsHA and NOD.scid.InsHA.IFNγRBnull
female mice (2×106 cells/mouse). BDC2.5 CD4+ T cells isolated from the spleen of 2-3 wk-
old nondiabetic BDC2.5.NOD.Cαnull mice were purified as described above and injected i.p.
(2×106 cells/mouse) into 6 to 8 wk-old NOD.scid.IFNγRBnull and NOD.scid female mice.
In some experiments 8.3 CD8+ T cells were co-transferred with CD4+ T cells. Here, 8.3
CD8+ and CD4+ T cells were isolated from the spleen of 5 wk-old 8.3-NOD and 12 wk-old
NOD female mice, respectively. NOD.scid and NOD.scid.IFNγRBnull mice 6-8 wks of age
received either 8.3 CD8+ T cells (2×106 cells/mouse) alone or both 8.3 CD8+ T cells and
NOD CD4+ T cells (2×106 cells/mouse).
Insulitis
Pancreases were removed, fixed in 10% formalin buffer (Fisher Scientific), and embedded
in paraffin. Serial sections were stained with H&E and non-overlapping sections evaluated
for insulitis as previously described [44]. Islets were scored as intact (no infiltration), peri-
insulitis (infiltrates surrounding the islet) and intra-insulitis (infiltrates within islets) which
was further scored as <50% and >50% infiltration.
Blood glucose tolerance test
IPGTT was performed as described [45, 46]. Briefly, mice were fasted for 12 hr and tested
for baseline of blood glucose levels prior to glucose administration. Mice were then injected
i.p. with a 10% glucose solution in PBS (3g/kg body weight) and blood glucose levels
measured (Abbott Diabetes Care Inc).
Bone marrow chimera
Bone marrow reconstitution experiments were carried out according to the method of
Tatekawa [26]. Briefly, bone marrow was prepared from femurs and tibias of 6 wk-old
NOD.scid or NOD.GFP mice and depleted of red blood cells. NOD.scid and
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NOD.scid.IFNγRBnull mice 6 wks of age were irradiated with 200 cGy using a gamma
irradiator and injected i.v. with 3×107 bone marrow cells 24 hr after irradiation. Eight wks
post-transplantation, bone marrow reconstitution was confirmed by examining GFP
expression by B cells and T cells. Chimeric NOD.scid and NOD.scid.IFNγRBnull mice were
then adoptively transferred with 2×106 BDC2.5 CD4+ T cells purified from
BDC2.5.NOD.Cαnull mice and monitored for diabetes.
In vitro β cell death
Islets were isolated and cytokine-induced β cell death was performed as described [47, 48].
Briefly, hand-picked islets were cultured for 4 days at 37°C in complete CMRL-1066
medium with recombinant cytokines (IFN-γ, 100 units/ml; IL-1β, 10 units/ml; and TNF-α,
1000 units/ml) (Peprotech). Islets were dispersed into single cells with 0.2% trypsin and 10
mM EDTA in Hank’s balanced salt solution, and cell death evaluated by flow cytometry
after staining with propidium iodide (Invitrogen).
In vivo T cell proliferation
CFSE-labeled BDC2.5 CD4+ T cells (2×106 cells/mouse) were injected i.v. into NOD.scid
and NOD.scid.IFNγRBnull mice. Cells were harvested from the spleen, PLN, MLN and
islets 4 and 6 days post-transfer and stained with mAbs (eBioscience, San Diego, CA)
specific for Vβ4, CD4, CD44 and CD62L. Proliferation and activation of BDC2.5 CD4+ T
cells were analyzed by flow cytometry (DakoCytomation).
Statistical analysis
Diabetes incidence was assessed with a Kaplan–Meier Log Rank Test (Prism,GraphPad, San
Diego, CA). The statistical analysis of β-cell death induced by cytokines was performed by
using the log-rank (Mantel–Cox) test (Prism,GraphPad, San Diego, CA).
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Figure 1. IFNγR deficiency in NOD.scid recipients prevents diabetes induction by BDC2.5 CD4+
T cells
A. Diabetes incidence in NOD.scid (Scid, n=10) and NOD.scid.IFNγRBnull (Scid.IFNγRB−/
−, n=10) mice adoptively transferred with splenocytes (1×107 cells/mouse) from diabetic
NOD mice; *P<0.0001. B. Diabetes incidence in NOD.scid.InsHA (Scid.InsHA, n=8) and
NOD.scid.InsHA.IFNγRBnull (Scid.InsHA.IFNγRB−/−, n=8) recipients of purified CL4
CD8+ T cells (2×106 cells/mouse) from the spleen of NOD.scid.CL4 mice; *P<0.0144. C.
Diabetes incidence in NOD.scid (Scid, n=5) and NOD.scid.IFNγRBnull (Scid.IFNγRB−/−,
n=6) recipients of purified BDC2.5 CD4+ T cells (2×106 cells/mouse) from the spleen of
NOD.BDC2.5.Cαnull mice; *P<0.0011.
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Figure 2. NOD.scid.IFNγRBnull recipients of BDC2.5 CD4+ T cells exhibit delayed onset and
progression of insulitis
Pancreases were harvested from NOD.scid.IFNγRBnull (IFNγRB−/−) recipients of BDC2.5
CD4+ T cells and evaluated for insulitis 5 and 15 wks post-transfer. Insulitis in NOD.scid
(Scid) recipients of BDC2.5 CD4+ T cells was examined 5 wks post-transfer. The data
presented in the figure shows the percentage of infiltrated islets of total islets examined in
individual animals. At least 50 islets per mouse were examined and bars represent individual
animals.
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Figure 3. IFNγR deficiency has no impact on the priming of BDC2.5 CD4+ T cells in the
pancreatic lymph nodes of NOD.scid.IFNγRBnull recipients
CFSE-labeled BDC2.5 CD4+ T cells were adoptively transferred into NOD.scid (Scid) and
NOD.scid.IFNγRBnull (IFNγRB−/−) mice. Cells were harvested from the PLN and islets 6
days after T cell transfer and stained with Abs specific for Vβ4, CD44, and CD62L.
Proliferation and activation of BDC2.5 CD4+ T cells in the PLN (A) and the islets (B) were
measured by CFSE dilution and the expression of CD44 and CD62L. Data shown are
representative of 3 experiments.
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Figure 4. β cells in NOD.scid.IFNγRBnull recipients of BDC2.5 CD4+ T cells exhibit normal
function, and are resistant to diabetes induction by CY-treatment
(A) NOD.scid.IFNγRBnull (Scid.IFNγRB−/−) recipients of BDC2.5 CD4+ T cells (n=6)
were injected (i.p.) with glucose solution (3 g/kg body weight) 20 wks post-transfer.
NOD.scid (Scid) mice (n=4) with no T cell transfer, NOD (Diabetic NOD) mice (n=2) with
recent onset of diabetes; and 10 wk-old pre-diabetic BDC2.5.NOD.Cαnull (BDC.Cα) mice
(n=5) were injected with glucose and served as controls. Blood glucose levels (mg/dl) were
measured after glucose injection. (B) NOD.scid.IFNγRBnull (Scid.IFNγRB−/−, n=14)
recipients of BDC2.5 CD4+ T cells were injected with CY (200ng/kg body weight) 20 wks
post-transfer. Pre-diabetic NOD.scid (Scid, n=4) recipients were injected with CY 5 wks
after T cell transfer. Pre-diabetic BDC2.5.NOD.Cαnull (BDC.Cα, n=5) mice receiving the
same treatment were used as controls. Data show the percentage of diabetes free animals.
*P<0.0001 for NOD.scid.IFNγRBnull recipients versus NOD.scid recipients or
BDC2.5.NOD.Cαnull mice. Data are representative of 3 experiments.
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Figure 5. Chimeric NOD.scid.IFNγRBnull mice are resistant to diabetes induced by BDC2.5
CD4+ T cells
NOD.scid.IFNγRBnull and NOD.scid mice were irradiated and reconstituted with bone
marrow from NOD.scid mice. Eight weeks after bone marrow reconstitution, the chimeric
NOD.scid.IFNγRBnull (Scid.IFNγRB−/−, n=8) and NOD.scid (Scid, n=10) mice were
adoptively transferred with purified BDC2.5 CD4+ T cells (2×106 cells/mouse) and followed
for the development of diabetes. The percentage of diabetes-free animals is shown.
*P<0.0034. Data are representative of 2 experiments.
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Figure 6. IFNγR-deficient β cells are resistant to proinflammatory cytokine-induced cell death in
vitro
Fresh islets isolated from NOD.scid (white bar) or NOD.scid.IFNγRBnull (black bar) mice
were cultured for 4 days in the presence of cytokines indicated. Cytokine-induced death of β
cells was determined by FACS after staining with propidium iodide. *P=0.0056;
**P=0.0122; ***P=0.0282. Data are representative of 3 experiments.
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Figure 7. CD4+ T cells accelerate the onset of diabetes induced by CD8+ T cells in
NOD.scid.IFNγRBnull mice
NOD.scid (A) and NOD.scid.IFNγRBnull (B) mice (6 to 8 mice per group) were adoptively
transferred (i.p.) with 8.3 CD8+ T cells (8.3) alone (2×106 cells/mouse;) or purified CD4+ T
cells (CD4) (2×106 cells/mouse) from 12-wk-old pre-diabetic NOD mice or co-transferred
with both CD4+ and 8.3 CD8+ T cells (CD4+8.3). The data show the percentage of diabetes-
free animals. *P=0.0121 for NOD.scid recipients of 8.3 versus CD4+8.3. †P=0.0109 for
NOD.scid.IFNγRBnull recipients of 8.3 versus CD4+8.3. Data shown are representative of
two experiments.
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